STRUGGLING to keep up with her two young children and dreading her own reflection in the mirror, Emma Lasenby knew something ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Find out all you need to know about Ozempic and other weight loss drugs, including the dangers and side effects ...

If that person loses 20 kilograms (44 pounds) in one year while taking a GLP-1R agonist — which is not unreasonable while ...

A new study conducted by researchers from the University of Eastern Finland the Karolinska Institutet explored the ways that ...

The company behind popular weight-loss drugs failed to disclose millions of pounds it paid to healthcare groups and patient ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Weight-loss supplements promise quick results but often lack scientific backing. Popular ingredients like caffeine, green tea extract, and fiber show limited benefits, while others like Garcinia ...

It brings the total number to nearly 400 in the six years since semaglutide and tirzepatide drugs like Wegovy, Mounjaro and Saxenda were ... people are using the weight-loss drugs in the UK ...